AT-7519 hydrochloride
CAS No. 902135-91-5
AT-7519 hydrochloride( AT 7519 Hydrochloride | AT7519 Hydrochloride )
Catalog No. M16486 CAS No. 902135-91-5
A potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 47 | In Stock |
|
| 10MG | 71 | In Stock |
|
| 25MG | 102 | In Stock |
|
| 50MG | 152 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAT-7519 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM).
-
DescriptionA potent CDK2 inhibitor with IC50 of 47 nM; also inhibits CDK1/4/5 with IC50 of 190/67/18 nM and shows selectivity over some kinases (Aurora A, IR kinase, MEK, PDK1, c-Abl, IC50>10 uM); has antiproliferative activity against HCT116 cells with IC50 of 82 nM; exhibits good profile against cytochrome P450 isoforms (<30% inhibition at 10 uM for 1A2, 2D6, 3A4, 2C9, 2C19).Blood Cancer Phase 2 Clinical(In Vitro):AT7519 (0-4 μM) results in dose-dependent cytotoxicity with IC50s ranging from 0.5 to 2 μM in MM cells, and this induced cytotoxicity is associated with GSK-3β activation independent of transcriptional inhibition. AT7519 overcomes proliferative advantage conferred by cytokines and the protective effect of BMSC. AT7519 (0.5 μM) induces apoptosis of MM cells in a time-dependent manner. Moreover, AT7519 (0.5 μM) inhibits phosphorylation of RNA polymerase II CTD and partially inhibits RNA synthesis in MM.1S cells. AT7519 (250 nM) inhibits cell cycle progression in human tumor cell lines. AT7519 also induces apoptosis of human tumor cell lines. AT7519 (100-700 nM) induces apoptosis in leukemia cell lines. AT7519 also inhibits transcription in human tumor cell lines. Furthermore, AT7519 inhibits RNA polymerase II and reduces antiapoptotic protein levels.(In Vivo):AT7519 inhibits tumor growth in a human MM xenograft mouse model. AT7519 (4.6 and 9.1 mg/kg/dose) inhibits the growth of early-stage HCT116 tumor xenografts. AT7519 (10 mg/kg, i.p.) also inhibits the target CDKs in HCT116 tumor-bearing BALB/c nude mice.
-
In Vitro——
-
In Vivo——
-
SynonymsAT 7519 Hydrochloride | AT7519 Hydrochloride
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK2/CyclinA|CDK4/CyclinD1|CDK5/p35|CDK9/CyclinT|GSK-3β
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number902135-91-5
-
Formula Weight418.7054
-
Molecular FormulaC16H18Cl3N5O2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCl.CC1=C(C(=O)NC2=C(NN=C2)C(=O)NC2CCNCC2)C(Cl)=CC=C1
-
Chemical Name1H-Pyrazole-3-carboxamide, 4-[(2,6-dichlorobenzoyl)amino]-N-4-piperidinyl-, hydrochloride (1:1)
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wyatt PG, et al. J Med Chem. 2008 Aug 28;51(16):4986-99.
2. Squires MS, et al. Mol Cancer Ther. 2009 Feb;8(2):324-32.
3. Dolman ME, et al. Clin Cancer Res. 2015 Nov 15;21(22):5100-9.
molnova catalog
related products
-
(S)-PF-06873600
(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.
-
Cdk2 Inhibitor II
Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.
-
CDK5-IN-3
CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA and can be used in the study of cancer.
Cart
sales@molnova.com